GPC3 and hepatocellular carcinoma: Another phase I trial involving 33 advanced HCC patients treated with GPC3 vaccine reported a mOS of 12.2 months (95% CI = 6.5-18.0) and 8.5 months (95% CI = 3.7-13.1) (p = 0.033) in patients with a high GPC3-related CTLs expressionand in those with a low GPC3-related CTL expression, respectively [75].